Brain Tumors Clinical Trial
Official title:
Effective and Safe Morphine Dose for Patient Controlled Anesthesia in Supratentorial Craniotomies
An optimal analgesic therapy is very important for postoperative recovery. In recent years, several studies showed that the prevalence of the moderate to severe pain after craniotomy ranged from 69 to 87% of patients. The investigators showed that the use of morphine based patient controlled analgesia prevented moderate to severe postoperative pain in patients undergoing supratentorial craniotomy. Morphine related side effects such as sedation, miosis, respiratory depression, nausea and vomiting produce a general reluctance for their use in neurosurgery. Therefore, all patients were closely observed to detect opioid related side effects in the intensive care unit for 24 hours following surgery in our previous study. The Integrated Pulmonary Index (IPI) is a new tool that calculates respiratory and hemodynamic parameters noninvasively. In the present study the investigators will use different doses of morphine based patient-controlled analgesia and the IPI system to determine more effective and safer morphine dose for postoperative analgesia following supratentorial craniotomy.
An optimal analgesic therapy is very important for postoperative recovery. In recent years,
several studies showed that the prevalence of the moderate to severe pain after craniotomy
ranged from 69 to 87% of patients. In our previous study, the investigators showed that the
use of morphine based patient controlled analgesia prevented moderate to severe postoperative
pain in patients undergoing supratentorial craniotomy. Morphine related side effects such as
sedation, miosis, respiratory depression, nausea and vomiting produce a general reluctance
for their use in neurosurgery. Therefore, all patients were closely observed to detect opioid
related side effects in the intensive care unit for 24 hours following surgery in our
previous study. The Integrated Pulmonary Index (IPI) is a new tool that calculates
respiratory and hemodynamic parameters noninvasively. In the present study The investigators
will use different doses of morphine based patient-controlled analgesia and the IPI system to
determine more effective and safer morphine dose for postoperative analgesia following
supratentorial craniotomy.
90 patients will randomize in 3 groups following supratentorial craniotomy. All patients will
previously instruct on the patient-controlled analgesia pumps (Abbott Provider, Chicago, USA)
and visual analogue scale (VAS) from 0 to 10, with 0 being no pain and 10 being the worst
pain imaginable. All patients will use patient-controlled analgesia pumps for 24 hours
following supratentorial craniotomy. In the Group 1 the patient-controlled analgesia pump
will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10
minutes and maximum 20 mg for 4 hours. In the Group 2 the patient-controlled analgesia pump
will set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10
minutes and maximum 20 mg for 4 hours. In the Group 3 the patient-controlled analgesia pump
will contain placebo. The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra
venous injections of dexketoprofen will repeat every 8 hours. If the VAS score will more than
4 the Group 3 patients will take 1 g paracetamol every 6 hours.
All patients will be observed by the Integrated Pulmonary Index (IPI). It is a new device
that provides to recognise in a patients respiratory status. This software tool is a single
index value ranging from 1 to 10 based on 4 physiological parameters: end tidal carbon
dioxide, respiratory rate, oxygen saturation, pulse rate. Patients will asses at 10th minute,
1, 2, 6, 12, and 24 hours postoperatively. Sedation will evaluate according to Ramsay score
20. VAS scores, total morphine consumption, Ramsay score, blood pressure, heart rate and
respiratory rate, the IPI score will record at each time pain will evaluate. Postoperative
side effects, including rash, pruritus, nausea and vomiting will record at the same intervals
and defined by a scale with 0 = absent or 1 = present. Moreover the lowest IPI score, the
apnea count (longer than 30 seconds) and the count of the desaturation events will record in
the postoperative 24 hours.
The 3 Groups will compare with respect to VAS scores, morphine consumption, IPI scores, the
apnea count, the desaturation events and morphine related side effects during the 24 hours
following supratentorial craniotomy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Completed |
NCT02537106 -
A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation
|
N/A | |
Completed |
NCT01951950 -
Nicardipine vs Esmolol Craniotomy Emergence
|
Phase 1 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00873184 -
Study of Massage Therapy Within a Brain Tumor Setting
|
N/A | |
Active, not recruiting |
NCT01115777 -
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
|
||
Completed |
NCT00003935 -
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
Completed |
NCT00724191 -
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
|
||
Recruiting |
NCT04128306 -
Brain Areas of Time-To-Contact Perception: an Awake Surgery Study
|
N/A | |
Recruiting |
NCT05202899 -
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
|
Phase 4 | |
Completed |
NCT00707343 -
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00850278 -
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
|
N/A | |
Completed |
NCT00528437 -
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
|
Phase 2 | |
Terminated |
NCT00107471 -
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT00135876 -
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
|
Phase 3 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Terminated |
NCT01018290 -
Navigated Transcranial Magnetic Stimulation in Tumor Surgery
|
N/A |